Celldex Therapeutics (NASDAQ:CLDX - Free Report) had its price target reduced by HC Wainwright from $50.00 to $42.00 in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company's stock.
A number of other analysts have also commented on the company. UBS Group decreased their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Morgan Stanley cut their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective for the company. Finally, The Goldman Sachs Group decreased their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $46.67.
View Our Latest Stock Report on Celldex Therapeutics
Celldex Therapeutics Stock Up 2.0%
Shares of CLDX traded up $0.44 on Wednesday, reaching $22.46. The stock had a trading volume of 1,797,765 shares, compared to its average volume of 1,313,527. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $47.00. The firm has a market capitalization of $1.49 billion, a PE ratio of -7.46 and a beta of 1.22. The firm has a 50-day moving average of $22.12 and a 200 day moving average of $20.64.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.The business had revenue of $0.73 million during the quarter, compared to analysts' expectations of $1.13 million. On average, sell-side analysts anticipate that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its stake in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 881 shares in the last quarter. Russell Investments Group Ltd. grew its position in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 501 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 2,933 shares during the period. Aquatic Capital Management LLC acquired a new position in shares of Celldex Therapeutics during the fourth quarter worth $121,000. Finally, Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics in the second quarter valued at $125,000.
Celldex Therapeutics Company Profile
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Read More
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access